Purpose: To evaluate vitreoretinal surgeons' access to operating rooms and potential barriers to care. Methods: An electronic survey of the American Society of Retina Specialists was performed in 2025. Results: Of the 276 respondents, most (90% [248]) were concerned about obtaining sufficient operating room time, with more than half (54% [150]) reporting increased difficulty accessing hospital operating rooms even during the weekdays and 45% (124) reporting increased difficulty accessing hospital operating rooms at nights and weekends. The most common reasons for limited access to operating rooms included block time/scheduling conflicts (61% [169]), anesthesia limitations (59% [162]), staffing limitations (51% [142]), and lower relative reimbursements for vitreoretinal surgeries (45% [125]). Most surgeons (94% [259]) believed that restricting operating room access adversely impacted patient care, leading to delays for urgent retinal detachment repairs (77% [212]), increased travel burden for patients (62% [170]), and worse patient outcomes (41% [113]). Patients treated in lower socioeconomic areas had to travel farther for surgery (median of 19 vs 9 miles for ambulatory surgery centers, P < .001, and 17 vs 9 miles for hospitals, P < .001). Practices have compensated by relying more on in-office procedures (46% [128]) and referrals to academic centers (39% [108]). Conclusions: Vitreoretinal surgeons were concerned about access restrictions to operating rooms and the potential impact on patients. Potential reasons for limited operating room access were likely multifactorial but included limited block time, restrictions in anesthesia and staff availability, and lower relative surgical reimbursements.
Purpose: To evaluate the outcomes of macular holes (MH) repaired using the viscostretch technique. Methods: This multicenter, multi-surgeon retrospective consecutive case series analyzed MH repaired with the viscostretch technique. Charts were retrospectively reviewed to assess baseline characteristics and outcomes. Results: Twenty eyes underwent complex MH repair with viscostretch. Baseline MH features included mean MH duration of 7 months (range, 0.75-18), baseline vision of 20/250 (20/50 to counting fingers), minimal linear MH diameter of 621 µm (range, 219-890), and maximal linear MH diameter of 1031 µm (range, 584-1498). MH were characterized by the presence of the following nonmutually exclusive complex MH features: recurrent/refractory MH (12/20 eyes [60%]); large MH (>400 µm minimal linear diameter, 17/20 eyes [85%]); and chronic MH (≥6 months duration, 10/20 eyes [50%]). Five of 20 eyes (25%) had large, chronic MH; 7 eyes (35%) had large, refractory/recurrent MH; 2 eyes (10%) had chronic, refractory/recurrent MH; and 4 eyes (20%) had large, chronic, refractory/recurrent MH. MH closure was achieved in 13 of 20 (65%) cases. There were no differences in baseline characteristics in eyes that achieved MH closure and those that did not. In eyes that achieved MH closure, there was a significant improvement in mean visual acuity from 20/200 to 20/100 ( P = .04). No surgical or postoperative complications were identified. Conclusions: The viscostretch surgical technique achieved MH closure in 65% of eyes in a cohort of various complex MH. Further studies are necessary to determine the use of this technique for complex MH.
PURPOSE:Vitrectomy with an internal limiting membrane (ILM) flap has been used in the repair of macular holes (MH). Topical drops have been attempted for smaller MHs with limited data. This study aims to demonstrate the effectiveness of a topical drop regimen in failing MHs after ILM flap surgery. METHODS:Review of 3 eyes with open MHs after vitrectomy with ILM flap. Preoperative visual acuity, MH size, tamponade used during surgery, time-to-hole closure, and final visual acuity were collected. RESULTS:Average MH size among all eyes was 743.3µm (+ 150.4). At the postoperative visit, the MHs were open. All eyes were started on topical steroid, nonsteroidal, and carbonic anhydrase inhibitor drops twice daily for a mean time of 33 days (+ 11 days). There was successful closure of the MHs with topical therapy in all cases. CONCLUSIONS:Topical therapy may aid in post-operative MH closure.
Purpose: To examine the rate and outcomes of secondary vitrectomies following pneumatic retinopexy for indications other than recurrent retinal detachment (RD). Methods: This was a retrospective consecutive case series reviewing the period from 2010 to 2020. Patients were included if they required a secondary vitrectomy after a successful pneumatic retinopexy for any indication, excluding recurrent RD. Indication and time between pneumatic retinopexy and secondary vitrectomy were the primary outcome measures. Results: A total of 296 eyes that underwent pneumatic retinopexy for primary RD repair were included in the study. Six eyes underwent secondary vitrectomy after successful pneumatic retinopexy. Indications for vitrectomy included 2 eyes with epiretinal membrane (0.7 %), 1 eye with full-thickness macular hole (0.3%), and 3 eyes with vitreous opacities (1.0 %). The mean (±SD) time to vitrectomy was 6 ± 5.7 months for epiretinal membrane, 22 ± 2.1 months for vitreous opacities, and 10 months for macular hole. Conclusions: Following pneumatic retinopexy for RD repair, 2% of eyes required vitrectomy for indications other than recurrent RD. Time to secondary vitrectomy varied among the indications. Patients should be counseled appropriately for the possibility of a secondary vitrectomy following a successful pneumatic retinopexy.